The tübingen-based Biotech company Curevac is apparently this Friday on the Nasdaq, such as information on the American technology stock exchange shows. The online appointment calendar of the Nasdaq, at 14. August will be the first time Curevac, offered shares to the public for sale.
editor in the economy.F. A. Z.
business correspondent in Stuttgart, Germany.F. A. Z. Twitter
Although it was already known for some time that the company would go to the stock exchange, further Details, however, were only communicated at the beginning of the week. Thus, the vaccine specialist, who is working on a vaccine against the Coronavirus could collect up to $ 245 million over the output of the first well of 13.3 million shares of common stock. In addition, signatories should be an Option of 30 days to purchase up to two million additional ordinary shares granted. The issue price has not been set yet, the price range per share should be between 14 and 16 dollars.
In Germany can buy investors, for example, via the Stuttgart stock exchange Curevac shares. "For private investors in this country, it is almost impossible in practice, through their Bank or their Online Broker on the drawing part," said Roland Hirsch müller, head of the foreign share trading of the Baader Bank, the Stuttgart stock exchange. But as soon as the Nasdaq-a first prize in the afternoon German time fixed, could be traded in the stock to the American stock exchange final in Stuttgart.
analysts and banks in America have a better knowledge of the industry
the German Biotech-company, as the stock exchange, the Nasdaq decided is not unusual, on the contrary, Five of the eleven European Biotech companies that have gone in the past year, the stock market, have chosen the Nasdaq, including Curevacs competitors Biontech from Mainz. "The re-election of the Nasdaq by a young German company, discloses the lack of attractiveness of IPOs in Germany relentlessly. This must change urgently,“ said Christine Bortenlänger, who sits on the Board of the German equities Institute.
the Biotech sector expert Siegfried Bialojan by the consulting firm EY sees three reasons for this: "The average income for a stock market are in America is significantly higher," he says, and cites as an example Curevacs American competitors Moderna, also a specialist for the genbasierte mRNA-technology. The Americans took almost two years ago, more than 600 million dollars.
the Nasdaq-access to the American market
That, in turn, spent in the capital ecosystem. "Both the analysts and the investment banks have Expertise, understand the business and have a euphoria for these technologies," he says. Finally, it also further increases in capital and financing, and were easier to get to. In this country, however, many banks have reduced their analysis departments, the Expertise delivered. "This Knowledge can also be not easy to get back," he says.Updated Date: 13 August 2020, 12:20